Ordinal outcomes add value to clinical trials - Authors' reply

Lancet. 2023 Mar 25;401(10381):995. doi: 10.1016/S0140-6736(23)00212-X.

Authors

Jason Weatherald¹, Marc Humbert²

Affiliations

¹ Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada.
² Faculty of Medicine, Université Paris-Saclay, Paris, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre 94270, France. Electronic address: [email protected].

PMID: 36965966
DOI: 10.1016/S0140-6736(23)00212-X

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticonvulsants* / therapeutic use
Drug Resistant Epilepsy* / drug therapy
Drug Therapy, Combination
Humans

Substances

Anticonvulsants